Gufic Biosciences Share Price
417.10+4.60 (+1.12%)
+14.20% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
LAURUSLABSNSE
CIPLANSE
DRREDDYNSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
GUFICBIONSE
Gufic Biosciences Share Price
417.10+4.60 (+1.12%)
+14.20% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | - | 15% |
| - | - | - | -8% |
| 28% | 17% | 14% | 14% |
| 13% | 13% | 13% | 10% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
LAURUSLABS
CIPLA
DRREDDY
MANKIND
AUROPHARMA
LUPIN
GUFICBIO
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,746.4 | ₹424466 Cr | 35.09 | 12.07 | 62.82 | ₹11479 Cr |
| 9,023 | ₹246222 Cr | 84.18 | 34.04 | 128.41 | ₹2568 Cr |
| 4,580 | ₹176301 Cr | 80.83 | 16.72 | 97.06 | ₹2163 Cr |
| 1,124.7 | ₹112818 Cr | 25 | 9.42 | 62.53 | ₹5040 Cr |
| 2,036.9 | ₹110823 Cr | 101.36 | 6.8 | 29.25 | ₹889 Cr |
| 1,314.6 | ₹107447 Cr | 31.88 | 9.77 | 57.87 | ₹3879 Cr |
| 1,216 | ₹103471 Cr | 32.11 | 5.32 | 63.99 | ₹4196 Cr |
| 2,335 | ₹97850 Cr | 47.9 | 13.75 | 71.08 | ₹1913 Cr |
| 1,662.9 | ₹96836 Cr | 26.08 | 17.95 | 96.84 | ₹3505 Cr |
| 1,953.2 | ₹89629 Cr | 16.21 | 30.95 | 154.35 | ₹5333 Cr |
| 416.5 | ₹4161 Cr | 56.65 | 2.23 | 10.4 | ₹64 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹261 Cr | ₹252 Cr | ₹231 Cr | ₹237 Cr | ₹224 Cr | ₹205 Cr | ₹208 Cr | ₹204 Cr | ₹203 Cr | ₹195 Cr | ₹202 Cr | ₹215 Cr |
| ₹46 L | -₹1 Cr | ₹79 L | ₹2 Cr | ₹93 L | ₹39 L | ₹2 Cr | ₹11 L | ₹1 Cr | ₹88 L | ₹42 L | ₹33 L |
| ₹261 Cr | ₹251 Cr | ₹232 Cr | ₹239 Cr | ₹225 Cr | ₹205 Cr | ₹210 Cr | ₹204 Cr | ₹204 Cr | ₹196 Cr | ₹202 Cr | ₹215 Cr |
| ₹222 Cr | ₹212 Cr | ₹206 Cr | ₹207 Cr | ₹198 Cr | ₹186 Cr | ₹178 Cr | ₹170 Cr | ₹171 Cr | ₹165 Cr | ₹169 Cr | ₹180 Cr |
| ₹47 Cr | ₹46 Cr | ₹34 Cr | ₹40 Cr | ₹34 Cr | ₹27 Cr | ₹36 Cr | ₹39 Cr | ₹37 Cr | ₹35 Cr | ₹37 Cr | ₹40 Cr |
| ₹9 Cr | ₹9 Cr | ₹8 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr |
| ₹30 Cr | ₹29 Cr | ₹18 Cr | ₹23 Cr | ₹17 Cr | ₹11 Cr | ₹26 Cr | ₹29 Cr | ₹28 Cr | ₹27 Cr | ₹30 Cr | ₹31 Cr |
| ₹22 Cr | ₹22 Cr | ₹12 Cr | ₹17 Cr | ₹13 Cr | ₹8 Cr | ₹19 Cr | ₹22 Cr | ₹21 Cr | ₹20 Cr | ₹22 Cr | ₹23 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| — | — | — |
| ₹10 Cr | ₹10 Cr | ₹10 Cr |
| ₹0 | ₹10 L | ₹0 |
| ₹655 Cr | ₹591 Cr | ₹523 Cr |
| ₹655 Cr | ₹591 Cr | ₹523 Cr |
| ₹665 Cr | ₹601 Cr | ₹533 Cr |
| ₹4 L | ₹0 | ₹0 |
| ₹105 Cr | ₹131 Cr | ₹154 Cr |
| ₹17 Cr | ₹8 Cr | ₹2 Cr |
| ₹20 Cr | ₹25 Cr | ₹17 Cr |
| ₹18 Cr | ₹17 Cr | ₹15 Cr |
| ₹160 Cr | ₹181 Cr | ₹188 Cr |
| — | — | — |
| ₹199 Cr | ₹159 Cr | ₹166 Cr |
| ₹58 Cr | ₹70 Cr | ₹56 Cr |
| ₹254 Cr | ₹154 Cr | ₹142 Cr |
| ₹6 Cr | ₹4 Cr | ₹7 Cr |
| ₹518 Cr | ₹388 Cr | ₹372 Cr |
| ₹1342 Cr | ₹1169 Cr | ₹1093 Cr |
| ₹12 Cr | ₹6 Cr | ₹7 Cr |
| ₹385 Cr | ₹310 Cr | ₹317 Cr |
| — | — | — |
| ₹630 Cr | ₹614 Cr | ₹246 Cr |
| ₹139 Cr | ₹108 Cr | ₹87 Cr |
| ₹491 Cr | ₹506 Cr | ₹159 Cr |
| ₹22 Cr | ₹22 Cr | ₹307 Cr |
| ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹24 Cr | ₹13 Cr | ₹23 Cr |
| ₹2 Cr | ₹2 Cr | ₹1 Cr |
| ₹540 Cr | ₹545 Cr | ₹492 Cr |
| — | — | — |
| ₹324 Cr | ₹217 Cr | ₹200 Cr |
| ₹297 Cr | ₹315 Cr | ₹330 Cr |
| ₹76 Cr | ₹29 Cr | ₹13 Cr |
| ₹2 Cr | ₹2 Cr | ₹4 Cr |
| ₹102 Cr | ₹63 Cr | ₹53 Cr |
| ₹802 Cr | ₹625 Cr | ₹600 Cr |
| ₹284 Cr | ₹237 Cr | ₹228 Cr |
| ₹1342 Cr | ₹1169 Cr | ₹1093 Cr |
| ₹66 | ₹60 | ₹53 |
| ₹66 | ₹60 | ₹53 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| ₹87 Cr | ₹94 Cr | ₹116 Cr |
| ₹65 Cr | ₹44 Cr | ₹34 Cr |
| -₹95 Cr | ₹7 Cr | -₹130 Cr |
| ₹57 Cr | ₹145 Cr | ₹20 Cr |
| ₹45 Cr | ₹123 Cr | -₹7 Cr |
| -₹31 Cr | -₹71 Cr | -₹102 Cr |
| ₹32 Cr | -₹37 Cr | ₹82 Cr |
| ₹46 Cr | ₹15 Cr | -₹27 Cr |
| ₹16 Cr | ₹1 Cr | ₹29 Cr |
| ₹62 Cr | ₹16 Cr | ₹1 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Gufic Biosciences Share Price
417.10+4.60 (+1.12%)
+14.20% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 1
Bearish signals: 3 out of 9 oscillators
RSI
47.83Neutral
STOCH %K
33.52Neutral
MACD Level(12,26)
-2.60Sell
Ultimate Oscillator
49.93Sell
Aroon Oscillator
50.00Neutral
BOP
0.15Buy
CCI
-70.89Neutral
Williams %R
-66.48Neutral
Momentum
-20.35Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 5 out of 9 moving averages
EMA 9
417.18Sell
SMA 9
416.33Buy
EMA 21
420.99Sell
SMA 21
423.97Sell
EMA 50
415.78Buy
SMA 50
423.05Sell
EMA 200
373.29Buy
SMA 200
348.92Buy
WMA 20
420.43Sell
Pivot
Pivot
Classic
Resistance 5
484.87
Resistance 4
467.17
Resistance 3
449.47
Resistance 2
431.77
Resistance 1
422.13
Pivot
414.07
Support 1
404.43
Support 2
396.37
Support 3
378.67
Support 4
360.97
Support 5
343.27
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Gufic Biosciences Share Price
417.10+4.60 (+1.12%)
+14.20% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 72.50% | 72.50% | 72.50% | 72.50% | 72.52% | 72.51% |
| 0.47% | 0.42% | 0.44% | 0.33% | 0.32% | 0.31% |
| 0.24% | 0.20% | 0.21% | 0.18% | 0.00% | 0.00% |
| 3.43% | 3.63% | 3.53% | 3.48% | 3.38% | 3.39% |
| 23.36% | 23.25% | 23.32% | 23.51% | 23.78% | 23.79% |
Bulk & block deals
Name
Graviton Research Capital Llp
Graviton Research Capital Llp
Financial Investors Trust A/C Grandeur Peak Global Opportunities Fund
Graviton Research Capital Llp
Graviton Research Capital Llp
Sbi Mutual Fund
Sbi Mutual Fund
Parth Infin Brokers Pvt. Ltd.
Parth Infin Brokers Pvt Ltd
Sbi Mutual Fund
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 30 Nov 2023 | Purchase | 19.38 Cr | ₹329.69 | 5.88 L | Bulk | 0.586131 | NSE |
| 30 Nov 2023 | Sell | 19.38 Cr | ₹329.72 | 5.88 L | Bulk | 0.586131 | NSE |
| 12 Aug 2021 | Purchase | 10.29 Cr | ₹205.89 | 5 L | Bulk | 0.498591 | NSE |
| 12 May 2021 | Purchase | 8.75 Cr | ₹190.06 | 4.60 L | Bulk | 0.458829 | NSE |
| 12 May 2021 | Sell | 8.74 Cr | ₹189.94 | 4.60 L | Bulk | 0.458829 | NSE |
| 18 May 2017 | Purchase | 19.23 Cr | ₹60.10 | 32 L | Bulk | 3.190985 | BSE |
| 18 May 2017 | Purchase | 13.04 Cr | ₹60.10 | 21.70 L | Bulk | 2.163887 | BSE |
| 18 May 2017 | Purchase | 10.11 Cr | ₹72.67 | 13.91 L | Bulk | 1.38739 | BSE |
| 18 May 2017 | Purchase | 5.13 Cr | ₹76.54 | 6.71 L | Bulk | 0.668683 | NSE |
| 18 May 2017 | Purchase | 3 Cr | ₹60.10 | 5 L | Bulk | 0.498591 | BSE |
Insider trading & SAST
Client name
Jayesh P Choksi & Pacs
Jayesh Choksi
Jayesh Choksi
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 03 Jun 2022 | Promoter | Disposal | 0.48 | 25.47 | 0 | — | 4.68 L | 02 Jun 2022 | Market | 2,46,90,829 | SAST | 29(2) | — |
| 03 Jun 2022 | Promoter & Director | Disposal | 0.018567 | 25.47 | 39.68 L | ₹220.43 | 18 K | 02 Jun 2022 | Market Sale | 2,46,90,829 | Insider Trading | — | Equity Shares |
| 03 Jun 2022 | Promoter & Director | Disposal | 0.464181 | 25.49 | 9.79 Cr | ₹217.65 | 4.50 L | 02 Jun 2022 | Market Sale | 2,47,08,829 | Insider Trading | — | Equity Shares |
Gufic Biosciences Share Price
417.10+4.60 (+1.12%)
+14.20% past 1 Year
Gufic Biosciences Limited is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on two recognised
Corporate Actions
Date
Type
Details
Company details
Gufic Biosciences Share Price
417.10+4.60 (+1.12%)
+14.20% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Gufic Biosciences Share Price
417.10+4.60 (+1.12%)
+14.20% past 1 Year
News
Gufic Biosciences rules out greenfield capex, limits spend to replacement needs
Equity
GUFICBIO
Gufic Biosciences maintains gross debt near Rs 400 crores for growth needs
Equity
GUFICBIO
Gufic Biosciences shares guidance for EBITDA margin expansion through FY2030
Equity
GUFICBIO
Gufic Biosciences projects steady annual improvement in gross margin profile
Equity
GUFICBIO
Gufic Biosciences issues revenue growth guidance indicating stronger FY performance outlook
Equity
GUFICBIO
Gufic Biosciences surges on getting nod to make further investment in Saraswat Co-operative Bank
Equity
GUFICBIO
Gufic Biosciences posts strong Q4 EBITDA growth with improved margins YoY
Equity
GUFICBIO
Gufic Biosciences Q4 FY earnings show strong profit and revenue growth
Equity
GUFICBIO
Gufic Biosciences gets nod to make further investment in Saraswat Co-operative Bank
Equity
GUFICBIO
Gufic Biosciences reports Profit after tax of 20.58 Crores, in the March 2026 quarter
Equity
GUFICBIO
Gufic Biosciences makes investment of $50,000 in Selvax
Equity
GUFICBIO
Gufic Biosciences invests USD 50,000 in Selvax Pty Ltd by acquiring 378,350 shares.
Equity
GUFICBIO
Gufic Biosciences reports Profit after tax of 15.56 Crores, in the December 2025 quarter
Equity
GUFICBIO
Gufic Biosciences Q3FY26 Earnings: Revenue Up 11%, EBITDA Growth 3.63%, PAT Down 19%.
Equity
GUFICBIO
Gufic BioSciences Q3FY26 Results: Revenue Up 11% YoY, Net Profit Down 19% YoY.
Equity
GUFICBIO
Gufic Biosciences targets strong export-led growth in injectables; Indore facility operational by FY26
Equity
GUFICBIO
Gufic Biosciences reports Profit after tax of 14.93 Crores, in the September 2025 quarter
Equity
GUFICBIO
Gufic Biosciences Q2 FY25 EBITDA declines YoY; EBITDA margin contracts on lower revenue.
Equity
GUFICBIO
Gufic Biosciences Q2 Net Profit and Revenue Update
Equity
GUFICBIO
Gufic Biosciences gains on making investment in Gufic Ireland
Equity
GUFICBIO